Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
about
The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer typesDetection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination.Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls.Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population.Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray.Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicityPrimary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cellsEpstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor originCharacterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma.Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma.A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma.Peripheral gamma delta T-cell deficit in nasopharyngeal carcinoma.Human genetic variants of homologous recombination repair genes first found to be associated with Epstein-Barr virus antibody titers in healthy Cantonese.Elevated Epstein-Barr virus seroreactivity among unaffected members of families with nasopharyngeal carcinoma.
P2860
Q33389641-616B75CB-E20F-4822-AC9E-A37DAE825F33Q33579452-0158F022-E4A9-4068-82E0-3C269B66D918Q33822681-7B7087A3-396C-446A-A345-B2C0E1E4F3DCQ34286259-67C7CE68-BFF7-4052-A04B-01792C6E7088Q35463816-D7E128D8-E574-4A54-BD7D-157D92821FF6Q35783467-783B791F-F3A8-44A4-9404-AC55206EF59BQ35857336-B65B402A-5AE5-40D4-B348-58DE3B0E09F1Q36124331-1E17A737-227F-4115-BA4B-766F5B8AC4BBQ36557221-F34143EA-842A-4680-B7EE-3DA5B7E4EBCCQ36609904-B926A10C-4E27-4714-AB07-B29042FBDDE5Q38172510-6D11750F-81E2-41C1-981D-6743C08244B0Q40735445-90F48D51-25C5-43B6-B231-DD77D42A1488Q43871340-BDB7128F-45D2-45A4-8D50-BFA41635D3A8Q45364179-9B2F52F2-0D77-4951-8910-AB8B6337C1B8
P2860
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
description
im Januar 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 February 2002
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2002
@uk
name
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
@en
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
@nl
type
label
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
@en
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
@nl
prefLabel
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
@en
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
@nl
P2093
P2860
P356
P1476
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
@en
P2093
Bo-jian Zheng
De-Kun Wang
Jin-sheng Liang
Jonathan S T Sham
Kwok Hung Chan
Mun Hon Ng
Rui-xian Luo
Wei-min Cheng
Winsie Luk
P2860
P304
P356
10.1002/IJC.1641
P577
2002-02-01T00:00:00Z